Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
1995-05-24
2008-11-11
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S141100, C424S143100, C424S172100, C530S387100, C530S388200, C530S388220
Reexamination Certificate
active
07449186
ABSTRACT:
A therapeutic method of modulating the immune response, by administering to a patient an amount of IL-4 effective to promote peripheral blood lymphocyte adhesion to microvascular endothelial cells in lymphoid organs. The IL-4 is preferably coadministered with IL-1β.An improved method of screening a cell line for the production of a binding partner that binds with a cell adhesion molecule, by contacting the binding partner with IL4-activated and nonactivated microvascular endothelial cells, and selecting binding partners that bind to the IL4-activated microvascular endothelial cells but not to the nonactivated microvascular endothelial cells. The selected binding partners may thereafter be tested for the ability to block lymphocyte binding to cytokine-activated endothelial cells. The binding partners are preferably also characterized by binding to human VCAM-1 and to IL4- or TNFα-activated bone marrow stromal cells. A representative embodiment is mAb 6G10 produced by hybridoma ATTC No. HB10519.A therapeutic method of modulating the immune response in a patient, by administering to the patient an agent that specifically binds to IL4-activated microvascular endothelial cells, in an amount effective to impede transmigration of lymphocytes that specifically bind to VCAM-1 from blood across postcapillary venules.
REFERENCES:
patent: 4803072 (1989-02-01), Dalton et al.
patent: 4851220 (1989-07-01), Yim et al.
patent: 4868119 (1989-09-01), Clark et al.
patent: 4894226 (1990-01-01), Aldwin et al.
patent: 4908433 (1990-03-01), Mertelsmann et al.
patent: 5011778 (1991-04-01), Newman et al.
patent: 5272263 (1993-12-01), Hession et al.
patent: 0 302 429 (1989-02-01), None
patent: 302429 (1989-02-01), None
patent: 0 408 859 (1991-01-01), None
patent: 0 410 750 (1991-01-01), None
patent: 0 505 749 (1992-09-01), None
patent: WO 90/07932 (1990-07-01), None
patent: WO90/07932 (1990-07-01), None
patent: WO 90/13300 (1990-11-01), None
patent: WO 91/05038 (1991-04-01), None
patent: WO 91/07186 (1991-05-01), None
patent: WO 91/14450 (1991-10-01), None
patent: WO 92/00751 (1992-01-01), None
patent: WO 92/03139 (1992-03-01), None
patent: WO 92/11030 (1992-07-01), None
patent: WO 92/12994 (1992-08-01), None
patent: WO 93/19770 (1993-10-01), None
Munro et al, Amer. J. of Pathology, vol. 135 No. 1 Jul. 1989 pp. 121-133.
Harris et al. TIBTECH 11: 42-45 (1993).
Edgington Biotechnology 10: 383-389(1992).
Perletler et al. J Immunol. 149: 2473-2481 (1992).
Simmons et al Blood 80: 388-395 (1992).
Graber et al. J Immunol. 175:819-830 (1990).
Shimizu et al. Immunol Rev. 114: 109-143 (1990).
Lewinsohn et al. Blood 75: 589-595 (1990).
Rice et al. J Exp Med 171: 1369-1374(1990).
Zanjani et al. Blood 84: 494a (1994) Abstract 1962.
Shaffer Biotech. Newswatch Oct. 4, 1993 p. 9.
Mountain et al. Biotech Gen Eng Rev. 10, 1, 10-13, Only (1992).
Hemler et al. Immunol. Today 9: 109-113 (1998).
Knapp et al. Leucocyte Typing IV Oxford Univ Press 1989 p. 1083, 1087 Only.
Lifsveld et al. Blood 81: 112-121 (1993).
Carter et al., “The induction of protective immunity toLeishmania majorin the BALB/c mouse by interleukin 4 treatment*”,Eur. J. Immunol., 19: 779-782 (1989).
Hart et al., “Potential antiinflammatory effects of interleukin 4: Suppression of Human monocyte tumor necrosis factor α, interleukin 1, and Prostaglandin E2,”,Proc. Natl. Acad. Sci, USA., 86: 3803-3807 (1989).
Thornhill et al., “IL-4 Regulates Endothelial Cell Activation by IL-1, Tumor Necrosis Factor, or IFN-γ1”,J. Immunol., 145: 865-872 (1990).
Masinovsky et al.,FASEB Journal3(3):A482, Mar. 1989.
Gallatin, W.M. et al., A cell-surface molecule involved in organ-specific homing of lymphocytes,Nature304:30-34, 1983.
Holzmann, B. et al., Identification of a murine Peyer's patch-specific lymphocyte homing receptor as an integrin molecule with an α chain homologous to human VLA 4α,Cell56:37-46, 1989.
Duijvestijn, A., and A. Hamann, Mechanisms and regulation of lymphocyte migration,Immunol. Today10:23-28, 1989.
Gallatin, W.M. et al., Lymphocyte homing receptors,Cell44:673-680, 1986.
Yednock, T.A., and S.D. Rosen, Lymphocyte homing,Adv. Immunol.44:313-378, 1989.
Woodruff, J.J., and L.M. Clarke, Specific cell-adhesion mechanisms determining migration pathways of recirculating lymphocytes,Ann. Rev. Immunol.5:201-222, 1987.
Rothlein, R., et al., A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1,J. Immunol.137:1270-1274, 1986.
Marlin, S.D., and T.A. Springer, Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen-1 (LFA-1),Cell51:813-819, 1987.
Cotran, R.S., New roles for the endothelium in inflammation and immunity,Am. J. Pathol.129:407-413, 1987.
Jalkanen, S., et al., A distinct endothelial cell recognition system that controls lymphocyte traffic into inflamed synovium,Science233:556-558, 1986.
Madri, J.A. et al., Matrix-driven cell size change modulates aortic endothelial cell proliferation and sheet migration,Am. J. Pathol.132:18-27, 1988.
Pals, S.T. et al., Mechanisms of human lymphocyte migration and their role in the pathogenesis of disease,Immunol. Rev.108:111-113, 1989.
Pober, J.S., Cytokine-mediated activation of vascular endothelium. Physiology and pathology,Am. J. Pathol.133:426-433, 1988.
Duijvestijn, A.M. et al., Interferon-γ regulates an antigen specific for endothelial cells involved in lymphocyte traffic,Proc. Natl. Acad. Sci. USA83:9114-9118, 1986.
Pohlman, T.H., and J.M. Harlan, Human endothelial cell response to lipopolysaccharide, interleukin-1, and tumor necrosis factor is regulated by protein synthesis,Cell Immunol.119:41-52, 1989.
Bevilacqua, M.P. et al., Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines,J. Clin. Invest.76:2003-2011, 1985.
Cavender, D.E. et al., Interleukin 1 increases the binding of human B and T lymphocytes to endothelial cell monolayers,J. Immunol.136:203-207, 1986.
Bevilacqua, M.P. et al., Identification of an inducible endothelial-leukocyte adhesion molecule,Proc. Natl. Acad. Sci. USA84:9238-9242, 1987.
Yu, C.L. et al., Human gamma interferon increases the binding of T lymphocytes to endothelial cells,Clin. Exp. Immunol.62:554-560, 1985.
Yu, C.L. et al., Effects of bacterial lipopolysaccharide on the binding of lymphocytes to endothelial cell monolayers,J. Immunol.136:569-573, 1986.
Cavender, D.E. et al., Stimulation of endothelial cell binding of lymphocytes by tumor necrosis factor,J. Immunol.139:1855-1860. 1987.
Issekutz, T.B., and J.M. Stoltz, Stimulation of lymphocyte migration by endotoxin, tumor necrosis factor, and interferon,Cell. Immunol.120:165-173, 1989.
Issekutz, T.B., Effects of six different cytokines on lymphocyte adherence to microvascular endothelium and in vivo lymphocyte migration in the rat,J. Immunol.144:2140-2146, 1990.
Kalaaji, A.N. et al., The enhancement of lymphocyte localization in skin sites of sheep of tumor necrosis factor alpha,Immunol. Letters23:143-148, 1989.
Stoolman, L.M., Adhesion molecules controlling lymphocyte migration,Cell56:907-910, 1989.
Dustin, M.L., and T.S. Springer, Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells,J. Cell Biol.107:321-331, 1988.
Rice, G.E., and M.P. Bevilacqua, An inducible endothelial cell surface glycoprotein mediates melanoma adhesion,Science246:1303-1306, 1989.
Osborn, L. et al., Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes,Cell59:1203-1211, 1989.
Elices, M.J. et al., VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site,Cell60:577-584, 1990.
Streeter, P.R. et al., Immunohistologic and functional characterization of vascular addressin involved in lymphocyte homing into peripheral lymph nod
Gallatin William Michael
Masinovsky Boris
Simmons Paul J.
Fred Hutchinson Cancer Research Center
Gambel Phillip
Myers Bigel Sibley & Sajovec P.A.
LandOfFree
Methods of blocking the interaction between stromal cells... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of blocking the interaction between stromal cells..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of blocking the interaction between stromal cells... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4041974